The Start of Germany’s National Pharma Strategy: Implications for CROs and Clinical Trials

Over the past decade, Germany’s share of global clinical trial activities has dropped year on year. The country accounted for just 3.9% of trials in 2021, down from 7.2% in 2012. Late last year, the German Government published its National Pharma Strategy, which is designed to reverse this trend. Aiming to revitalize the country’s pharmaceutical … Read more

Velocity Enrolled 8,000+ Participants in Trials in October

Velocity enrolled more than 8,000 participants in clinical trials in October, marking our highest-ever enrollment in a single month. This required many long hours and thoughtful solutioning from so many across the organization. A special thank you to our site staff and Recruitment team, who continuously rise to every challenge and keep patient care and … Read more

Velocity Named Among the Top 50 Operations Teams at the 2024 OnCon Icon Awards

Velocity has been recognized among the Top 50 Operations Teams at the 2024 OnCon Icon Awards! This award is especially meaningful because it’s based on peer and community votes, reflecting the operational excellence our team continues to build as we scale globally. Thank you to OnConferences, to everyone who voted, and to our exceptional team … Read more

Scaling With a Purpose: Championing the Clinical Trials Sector

At the beginning of September, Velocity Clinical Research topped Business North Carolina’s 2024 Fast 40 list. It was our third time receiving the award, which recognizes the fastest-growing mid-market businesses in the state. For a clinical trials organization to achieve this level of scale is notable. The clinical trials sector in the US is typically … Read more

ACRP Article: Providing the Blueprint for Gen AI Adoption in Clinical Trials

In his latest article for the Association of Clinical Research Professionals (ACRP), Paul Evans outlines how integrated site organizations can pave the way for AI adoption and generate tangible value for the industry. For sites, investigators, and patients, Gen AI has the potential to streamline recruitment, reduce manual labor, and accelerate trial processes. By leveraging … Read more

Nick Spittal Comments on Velocity’s Membership With Advarra’s Gene Therapy Ready Site Network

As Nick Spittal states in this Advarra press release, membership in the Gene Therapy Ready (GTR) site network “allows Velocity to start studies over a month faster and provides a meaningful credential and important validation that increases sponsors’ confidence in our specialized capabilities to conduct complex clinical research safely.” All Velocity sites are fully prepared … Read more

VISION Reaches $2.5 Million in Patient Stipends Paid Globally

Another major milestone for Velocity — more than $2.5 million in patient study stipends have been paid globally through our VISION Engage app! With VISION Engage, patients can seamlessly manage their trial journey while receiving study stipends directly through the app, making participation more convenient. Together with VISION Engage app users, we’re transforming clinical trial … Read more

Dr. Watz Publishes 250th Paper, Leads Velocity’s Ahrensburg, Germany Site as the Top Enroller for a Global COPD Trial

Congratulations to Henrik Watz, MD, PhD, and our site in Ahrensburg (formerly Velocity Grosshansdorf), Germany, which is currently the top enroller for a global COPD trial! Dr. Watz has just published his 250th full paper, detailing results from the Phase 2 AIRLEAF trial. This study could pave the way for new treatment options in bronchiectasis, … Read more